Press Releases

Mooresville, NC – May 13, 2014 – Nukepills.com announces today that the U.S. Department of Health and Human Services (HHS) was recently shipped 6,383,000 tablets of FDA approved potassium iodide for protection against radiation in the event of a nuclear reactor accident. The balance of the total 14 million tablet solicitation by HHS, on behalf of the Nuclear Regulatory Commission (NRC), is scheduled for delivery by the end of 2014. Full Press Release

Mooresville, NC – March 15, 2011 –– Approximately 54,000 potassium iodide tablets have been donated by Nukepills.com to Tokushukai Hospital in Tokyo, Japan for immediate distribution to those affected by Japan’s nuclear reactor crisis. This effort was facilitated by Dr. Alisa Suzuki Han, Radiologist at Brigham and Women’s Hospital, a teaching facility of Harvard Medical School, in Boston, MA. The radiation-blocking drug, currently in route to Japan, will be distributed by the Tokushukai Medical Aid Team. “We are very pleased that these tablets will be given to people directly affected by the nuclear crisis”, stated Troy Jones, President of Nukepills.com, “The efforts of Dr. Han and the Tokushukai Medical Aid Team are a wonderful example of professionals coming together to ensure the health and livelihood of those most in need.” Full Press Release

Mooresville, NC – January 26, 2009 –– Nukepills.com today announced the sale of 180,000 units (5.4 million doses) of ThyroShield™ Potassium Iodide to the Kuwait Ministry of Health. Worth approximately $1.4 million, the sale was brokered by Nukepills.com and signifies Kuwait’s proactive course in protecting its citizens during a nuclear radiation emergency.

“This sale is the first large-scale order of ThyroShield from a foreign government. We are currently working on additional potassium iodide orders from other countries in the Middle East, Europe and Asia.”, said Troy Jones, President of Nukepills.com. “We hope the new U.S administration follows Kuwait’s lead and reinstates and expands the potassium iodide distribution plan to protect its citizens.”

ThyroShield™ Potassium Iodide Oral Solution is a ready-to-use, thyroid-blocking liquid medicine for radiation emergencies. Stockpiling of potassium iodide is recommended by health officials worldwide to prevent thyroid cancer in those exposed to radioactive iodine in the event of a nuclear reactor accident or fallout from a nuclear weapon. Potassium iodide protects against the harmful effects of radioactive iodine by preventing its absorption by the thyroid gland. Thyroid cells are the only cells in the human body that can absorb iodine, and are thus the only cells at risk for cancer. Full Press Release